Amedisys (NASDAQ:AMED) Now Covered by StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Amedisys (NASDAQ:AMED) in a research note issued to investors on Monday. The firm set a “buy” rating on the health services provider’s stock.

Several other equities research analysts also recently weighed in on AMED. Benchmark downgraded Amedisys from a “buy” rating to a “hold” rating in a research report on Tuesday, June 27th. Credit Suisse Group downgraded Amedisys from an “outperform” rating to a “neutral” rating in a research report on Tuesday, June 6th. TD Cowen increased their price target on Amedisys from $84.00 to $101.00 and gave the stock a “market perform” rating in a research report on Monday, July 31st. SVB Securities cut their price target on Amedisys from $96.00 to $81.00 in a research report on Friday, May 5th. Finally, Jefferies Financial Group downgraded Amedisys from a “buy” rating to a “hold” rating in a research report on Thursday, July 6th. Ten investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $109.60.

Amedisys Stock Performance

Shares of AMED stock opened at $93.25 on Monday. The firm has a market capitalization of $3.04 billion, a price-to-earnings ratio of 1,332.14, a price-to-earnings-growth ratio of 2.54 and a beta of 1.04. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.92 and a quick ratio of 0.92. The business has a fifty day moving average of $91.59 and a 200 day moving average of $85.46. Amedisys has a 1 year low of $69.36 and a 1 year high of $128.28.

Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, July 26th. The health services provider reported $1.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.28. The company had revenue of $552.97 million during the quarter, compared to analyst estimates of $568.18 million. Amedisys had a return on equity of 14.00% and a net margin of 0.10%. The firm’s quarterly revenue was down .9% on a year-over-year basis. During the same quarter last year, the business posted $1.47 EPS. As a group, research analysts expect that Amedisys will post 4.42 earnings per share for the current year.

Institutional Investors Weigh In On Amedisys

Several institutional investors have recently bought and sold shares of AMED. Raymond James & Associates boosted its holdings in Amedisys by 6.5% in the 1st quarter. Raymond James & Associates now owns 11,101 shares of the health services provider’s stock worth $1,913,000 after buying an additional 680 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its stake in Amedisys by 9.2% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 2,397 shares of the health services provider’s stock worth $413,000 after purchasing an additional 202 shares in the last quarter. Cambridge Investment Research Advisors Inc. lifted its stake in Amedisys by 22.1% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 3,425 shares of the health services provider’s stock worth $590,000 after purchasing an additional 620 shares in the last quarter. HighTower Advisors LLC lifted its stake in Amedisys by 40.4% in the 1st quarter. HighTower Advisors LLC now owns 7,619 shares of the health services provider’s stock worth $1,310,000 after purchasing an additional 2,193 shares in the last quarter. Finally, Citigroup Inc. lifted its stake in Amedisys by 6.4% in the 1st quarter. Citigroup Inc. now owns 13,268 shares of the health services provider’s stock worth $2,287,000 after purchasing an additional 803 shares in the last quarter. 94.85% of the stock is currently owned by institutional investors and hedge funds.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.